In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates

被引:143
作者
Owen, Roxanne J. [1 ]
Li, Jian [1 ]
Nation, Roger L. [1 ]
Spelman, Denis [1 ]
机构
[1] Monash Univ, Victorian Coll Pharm, Facil Antiinfect Drug Dev & Innovat, Parkville, Vic 3052, Australia
基金
英国医学研究理事会;
关键词
killing kinetics; heteroresistance; post-antibiotic effect;
D O I
10.1093/jac/dkl512
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background. Colistin is being increasingly used for treatment of infections caused by multidrug-resistant Gram-negative bacteria, including Acinetobacter baumannii. Methods: The in vitro pharmacodynamic properties of colistin (sulphate) were investigated by studying the time-kill kinetics and the post-antibiotic effect (PAE) against multidrug-resistant, including colistin heteroresistant, A. baumannii. Time-kill was studied with four multidrug-resistant clinical isolates at concentrations ranging from 0.5 to 64x MIC. The PAE was examined after 20 min exposure with five clinical isolates, including the four in the time-kill study, plus ATCC 19606. Results: Colistin showed extremely rapid killing in a concentration-dependent manner; but re-growth was observed as early as 3 h and substantial re-growth at 24 h even at concentrations up to 32x MIC or 64x MIC for some isolates. Colistin exhibited modest PAE of 1.0, 2.3 and 3.5 h at 16, 32 and 64x MIC, respectively, against ATCC 19606. Surprisingly, negative PAE (range: -0.8 to -8.15 h) was observed for all of the five clinical isolates. Conclusions: These findings suggest that monotherapy with colistin methanesulphonate, the parenteral form of colistin, and long dosage intervals (e.g. 24 h) may be problematic for treatment of infections caused by colistin heteroresistant A. baumannii.
引用
收藏
页码:473 / 477
页数:5
相关论文
共 23 条
  • [11] Multidrug-resistant Acinetobacter infections:: An emerging challenge to clinicians
    Jain, R
    Danziger, LH
    [J]. ANNALS OF PHARMACOTHERAPY, 2004, 38 (09) : 1449 - 1459
  • [12] Koyama Y., 1950, J.Antibiot, V3, P457
  • [13] Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration
    Li, J
    Rayner, CR
    Nation, RL
    Deans, R
    Boots, R
    Widdecombe, N
    Douglas, A
    Lipman, J
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (11) : 4814 - 4815
  • [14] Evaluation of colistin as an agent against multi-resistant in Gram-negative bacteria
    Li, J
    Nation, RL
    Milne, RW
    Turnidge, JD
    Coulthard, K
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2005, 25 (01) : 11 - 25
  • [15] Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis
    Li, J
    Coulthard, K
    Milne, R
    Nation, RL
    Conway, S
    Peckham, D
    Etherington, C
    Turnidge, J
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (06) : 987 - 992
  • [16] In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis
    Li, J
    Turnidge, J
    Milne, R
    Nation, RL
    Coulthard, K
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) : 781 - 785
  • [17] Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
    Li, Jian
    Nation, Roger L.
    Turnidge, John D.
    Milne, Robert W.
    Coulthard, Kingsley
    Rayner, Craig R.
    Paterson, David L.
    [J]. LANCET INFECTIOUS DISEASES, 2006, 6 (09) : 589 - 601
  • [18] Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii
    Li, Jian
    Rayner, Craig R.
    Nation, Roger L.
    Owen, Roxanne J.
    Spelman, Denis
    Tan, Kar Eng
    Liojios, Lisa
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (09) : 2946 - 2950
  • [19] Old Polymyxins are back: Is resistance close?
    Li, Jian
    Nation, Roger L.
    [J]. CLINICAL INFECTIOUS DISEASES, 2006, 43 (05) : 663 - 664
  • [20] The threat from the pink corner
    Livermore, DM
    [J]. ANNALS OF MEDICINE, 2003, 35 (04) : 226 - 234